Tezepelumab, a humanized monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), has demonstrated promise in reducing eosinophilic inflammation, airway hyperresponsiveness, and asthma exacerbations. Here, TSLP is linked to inflammation.